Literature DB >> 22219276

Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease.

Wanda Kwan1, Anna Magnusson, Austin Chou, Anthony Adame, Monica J Carson, Shinichi Kohsaka, Eliezer Masliah, Thomas Möller, Richard Ransohoff, Sarah J Tabrizi, Maria Björkqvist, Paul J Muchowski.   

Abstract

Huntington's disease (HD) is caused by an expanded polyglutamine tract in the protein huntingtin (htt). Although HD has historically been viewed as a brain-specific disease, htt is expressed ubiquitously, and recent studies indicate that mutant htt might cause changes to the immune system that could contribute to pathogenesis. Monocytes from HD patients and mouse models are hyperactive in response to stimulation, and increased levels of inflammatory cytokines and chemokines are found in pre-manifest patients that correlate with pathogenesis. In this study, wild-type (WT) bone marrow cells were transplanted into two lethally irradiated transgenic mouse models of HD that ubiquitously express full-length htt (YAC128 and BACHD mice). Bone marrow transplantation partially attenuated hypokinetic and motor deficits in HD mice. Increased levels of synapses in the cortex were found in HD mice that received bone marrow transplants. Importantly, serum levels of interleukin-6, interleukin-10, CXC chemokine ligand 1, and interferon-γ were significantly higher in HD than WT mice but were normalized in mice that received a bone marrow transplant. These results suggest that immune cell dysfunction might be an important modifier of pathogenesis in HD.

Entities:  

Mesh:

Year:  2012        PMID: 22219276      PMCID: PMC3571858          DOI: 10.1523/JNEUROSCI.4846-11.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  51 in total

1.  Formation of polyglutamine inclusions in non-CNS tissue.

Authors:  K Sathasivam; C Hobbs; M Turmaine; L Mangiarini; A Mahal; F Bertaux; E E Wanker; P Doherty; S W Davies; G P Bates
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

Review 2.  The role of immunity in Huntington's disease.

Authors:  D Soulet; F Cicchetti
Journal:  Mol Psychiatry       Date:  2011-04-26       Impact factor: 15.992

3.  Activated immune system in patients with Huntington's disease.

Authors:  F Leblhuber; J Walli; K Jellinger; G P Tilz; B Widner; F Laccone; D Fuchs
Journal:  Clin Chem Lab Med       Date:  1998-10       Impact factor: 3.694

Review 4.  Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology.

Authors:  N J Rothwell; G Luheshi; S Toulmond
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

5.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease.

Authors:  N Stoy; G M Mackay; C M Forrest; J Christofides; M Egerton; T W Stone; L G Darlington
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

6.  Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.

Authors:  Daniel Zwilling; Shao-Yi Huang; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Paolo Guidetti; Hui-Qiu Wu; Jason Lee; Jennifer Truong; Yaisa Andrews-Zwilling; Eric W Hsieh; Jamie Y Louie; Tiffany Wu; Kimberly Scearce-Levie; Christina Patrick; Anthony Adame; Flaviano Giorgini; Saliha Moussaoui; Grit Laue; Arash Rassoulpour; Gunnar Flik; Yadong Huang; Joseph M Muchowski; Eliezer Masliah; Robert Schwarcz; Paul J Muchowski
Journal:  Cell       Date:  2011-06-10       Impact factor: 41.582

7.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout
Journal:  Lancet Neurol       Date:  2010-12-02       Impact factor: 44.182

8.  Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits.

Authors:  Sofia Hult; Rana Soylu; Tomas Björklund; Bengt F Belgardt; Jan Mauer; Jens C Brüning; Deniz Kirik; Åsa Petersén
Journal:  Cell Metab       Date:  2011-04-06       Impact factor: 27.287

9.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

Review 10.  Presymptomatic detection of Huntington's disease.

Authors:  D N Propert
Journal:  Med J Aust       Date:  1980-06-14       Impact factor: 7.738

View more
  35 in total

Review 1.  The choreography of neuroinflammation in Huntington's disease.

Authors:  Andrea Crotti; Christopher K Glass
Journal:  Trends Immunol       Date:  2015-05-20       Impact factor: 16.687

2.  Modeling an autism risk factor in mice leads to permanent immune dysregulation.

Authors:  Elaine Y Hsiao; Sara W McBride; Janet Chow; Sarkis K Mazmanian; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

Review 3.  Peripheral inflammation in neurodegeneration.

Authors:  Ulrike Träger; Sarah J Tabrizi
Journal:  J Mol Med (Berl)       Date:  2013-04-02       Impact factor: 4.599

4.  Mutant huntingtin impairs immune cell migration in Huntington disease.

Authors:  Wanda Kwan; Ulrike Träger; Dimitrios Davalos; Austin Chou; Jill Bouchard; Ralph Andre; Aaron Miller; Andreas Weiss; Flaviano Giorgini; Christine Cheah; Thomas Möller; Nephi Stella; Katerina Akassoglou; Sarah J Tabrizi; Paul J Muchowski
Journal:  J Clin Invest       Date:  2012-11-19       Impact factor: 14.808

5.  Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.HttQ111/+ model of Huntington's disease.

Authors:  Robert M Bragg; Sydney R Coffey; Rory M Weston; Seth A Ament; Jeffrey P Cantle; Shawn Minnig; Cory C Funk; Dominic D Shuttleworth; Emily L Woods; Bonnie R Sullivan; Lindsey Jones; Anne Glickenhaus; John S Anderson; Michael D Anderson; Stephen B Dunnett; Vanessa C Wheeler; Marcy E MacDonald; Simon P Brooks; Nathan D Price; Jeffrey B Carroll
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

6.  Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease.

Authors:  Sydney R Coffey; Robert M Bragg; Shawn Minnig; Seth A Ament; Jeffrey P Cantle; Anne Glickenhaus; Daniel Shelnut; José M Carrillo; Dominic D Shuttleworth; Julie-Anne Rodier; Kimihiro Noguchi; C Frank Bennett; Nathan D Price; Holly B Kordasiewicz; Jeffrey B Carroll
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

7.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

Review 8.  The role of microglia in brain maintenance: implications for Rett syndrome.

Authors:  Noël C Derecki; James C Cronk; Jonathan Kipnis
Journal:  Trends Immunol       Date:  2012-10-31       Impact factor: 16.687

9.  Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation.

Authors:  Yue Yang; Nikolas L Jorstad; Christine Shiao; Makenzie K Cherne; Shawn B Khademi; Kathleen S Montine; Thomas J Montine; C Dirk Keene
Journal:  Exp Mol Pathol       Date:  2013-04-06       Impact factor: 3.362

10.  Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.

Authors:  Andreas Weiss; Ulrike Träger; Edward J Wild; Stephan Grueninger; Ruth Farmer; Christian Landles; Rachael I Scahill; Nayana Lahiri; Salman Haider; Douglas Macdonald; Chris Frost; Gillian P Bates; Graeme Bilbe; Rainer Kuhn; Ralph Andre; Sarah J Tabrizi
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.